Why We Should Target Small Airways Disease in Our Management of Chronic Obstructive Pulmonary Disease

Omar S. Usmani, FRCP; Rajiv Dhand, MD; Federico Lavorini, PhD; and David Price, FRCGP

Abstract

For more than 50 years, small airways disease has been considered a key feature of chronic obstructive pulmonary disease (COPD) and a major cause of airway obstruction. Both preventable and treatable, small airways disease has important clinical consequences if left unchecked. Small airways disease is associated with poor spirometry results, increased lung hyperinflation, and poor health status, making the small airways an important treatment target in COPD. The early detection of small airways disease remains the key barrier; if detected early, treatments designed to target small airways may help reduce symptoms and allow patients to maintain their activities. Studies are needed to evaluate the possible role of new drugs and novel drug formulations, inhalers, and inhalation devices for treating small airways disease. These developments will help to improve our management of small airways disease in patients with COPD.

F o r m o r e t h a n 5 0 y e a r s , s m a l l a i r w a y s d i s e a s e h a s b e e n i d e n t i f i e d a s a m a j o r cause of airway obstruction, particularly early in the course of chronic obstructive pulmonary disease (COPD).1-4 Although somewhat underrecognized in daily clinical practice,5 small airways disease is reported in at least three-quarters of patients with COPD.6 Indeed, given the difficulties in assessing small airway abnormalities, which we describe later in this article, it is likely that small airways dysfunction is a common factor in all patients with COPD, coexisting in differing degrees with other phenotypic variations of this complex and heterogeneous disease.

Also known as peripheral airways, the small airways (<2 mm in diameter) include bronchioles, terminal bronchioles, respiratory bronchioles, alveolar ducts, and alveolar sacs (Figure 1A). The term “small airways disease” was first coined in 1968 and identified as the major cause of airway resistance in patients with obstructive lung disease.7 More recently, the role of small airways disease in the pathogenesis of COPD has been recognized by the Global Initiative for Chronic Obstructive Lung Disease (GOLD)7 and Interasma/the World Allergy Organization.8 Notably, the documented prevalence of small airways disease (74%-83%)9 increases with rising GOLD classification, indicating that it is progressive and worsens with increasing severity of COPD.6 Small airways disease is particularly notable (~93%) in patients with a high effect of COPD on health status and daily life.9 The fact that small airways are involved in the development of airflow limitation in both predominant COPD phenotypes—emphysema and chronic bronchitis—indicates their prominent role in the pathogenesis of the condition.3,10,11

METHODS

The aims of this focused review were to summarize key information on the pathophysiology of small airways disease, how it is assessed, and why it is an important
treatment target as well as to review available treatments and future directions in the management of the condition. Studies included in this article were identified by searching the PubMed (MEDLINE) database, using the search terms COPD AND (“small airway disease” OR “small airways disease” OR “small airway dysfunction” OR “small airways dysfunction”) and by cross-referencing citations in identified studies that were available in print or online, including relevant studies in patients with asthma.

PATHOPHYSIOLOGY

Airway Remodeling, Mucus Plugging, and Immune Cell Infiltration

In COPD, small airways disease is characterized by airway remodeling, mucus plugging, and immune cell infiltration (Figure 1B). Injury caused by factors such as cigarette smoke or infection triggers the wound healing process, resulting in an increase in airway wall thickness and therefore a decrease in the airway lumen. Cigarette smoking also induces hypersecretion of mucus, leading to mucus plugging and physical blockage of airflow. This is compounded by the effect of smoking in reducing cilia length in the small airways, leading to decreased mucociliary clearance. Mucus may also harbor pathogenic microorganisms that promote inflammation and tissue destruction. Immune cell infiltration involves the recruitment of increased numbers of macrophages, neutrophils, CD20 B cells, and CD4+ and CD8+ T cells to the small airways, with CD8+ T cells hypothesized to be the predominant inflammatory cells contributing to small airway obstruction and tissue damage.

Evidence Early in the Course of COPD

Small airways disease is often evident before the onset of symptoms or changes in spirometry or imaging findings in COPD. The small airways represent a “silent zone” in the normal lung in which defects can accumulate without being noticed; this finding has led to the development of specialized tests to detect early abnormalities in the hope of preventing or delaying disease progression. However, traditional imaging techniques may not be sufficiently sensitive to identify the early stages of small airways disease or to differentiate between the contribution of small airways disease and emphysema. Because extensive small airways damage and obliteration can occur before it is detectable with conventional spirometric tests, spirometry is also of limited use as a screening tool for early disease. Small airways disease may be a precursor to emphysema. Very severe COPD is associated with a marked reduction in both the number of terminal bronchioles and the minimal lumen caliber of those that remain. These changes can be present in regions of the lungs not yet affected by emphysema, suggesting that they may begin at very early stages in the natural history of COPD. Other studies have reported that both small airways disease and emphysema are associated with decline in forced expiratory volume in 1 second (FEV1), but small airways disease has a greater role in the decline associated with mild-to-moderate airflow limitation, which indicates a role early in the disease course.

ARTICLE HIGHLIGHTS

- Small airways disease is a key feature of chronic obstructive pulmonary disease (COPD) and a major cause of airway obstruction.
- Patients with COPD and small airways disease have worse spirometry results, more severe lung hyperinflation, and poorer health status compared with those without small airways disease, making the small airways an important treatment target.
- In this article, we evaluate several new techniques that have the potential to achieve the early detection of small airways disease.
- We review therapy options designed to target the small airways that may help reduce symptoms and allow patients to maintain their activities.
- Advances in our ability to assess the extent of small airways involvement, as well as the use of novel drugs, formulations, and inhalers that target the small airways, will help to improve our management of small airways disease in patients with COPD.
Effect of Small Airways Disease on Hyperinflation

Pulmonary hyperinflation is a common cause of dyspnea and functional limitation in patients with COPD. Small airways disease can lead to expiratory flow limitation, gas trapping within the lung and dynamic hyperinflation. This is characterized by flattening of the diaphragm, sternal bowing, chest kyphosis, and enlarged intercostal spaces, resulting in a barrel chest. Dynamic hyperinflation develops as a result of expiratory airflow limitation coupled with decreased exhalation time, for example, during exercise, and is associated with decreased inspiratory capacity and increased functional residual capacity (Figure 2).

Hyperinflation affects clinical outcomes in COPD; for example, activity-related dyspnea associated with hyperinflation can lead to a vicious cycle of activity avoidance, physical deconditioning, and reduced health-related quality of life. Indeed, dynamic hyperinflation and exercise limitation are both independent predictors of mortality in patients with COPD. Hyperinflation also has implications for the early development of comorbidities such as cardiovascular disease. Of particular concern, hyperinflation impairs the mechanical function of the respiratory muscles and has adverse effects on the cardiocirculatory system.

Role of Bacterial Colonization and Exacerbations

Bacterial colonization and exacerbations (or acute clinical deterioration) of COPD both have a role in the progression of small airways disease. Bacterial colonization is aggravated by reduced clearance and decreased antimicrobial activity of mucus in patients with COPD. This can lead to chronic low-grade inflammation, which at times can increase acutely,
leading to an exacerbation. Furthermore, acute exacerbations are often associated with new strains of colonizing bacteria, supporting a causative role of bacteria in the onset of exacerbations. Exacerbations of COPD also appear to play a part in the airway remodeling process, by promoting rapid turnover of the extracellular matrix (including increases in degradation fragments of collagens I, IV, and VI and the pro-form of collagen V), increasing sputum neutrophils and neutrophil proteases, increasing expression and activity of matrix metalloproteinases, and dysregulating proteinase activity. These effects, in turn, lead to tissue destruction and reduced mobility of mucus.

**CLINICAL EFFECT**

Small airways disease is associated with poor spirometry results, increased lung hyperinflation, and poor health status, making the small airways an important treatment target in COPD. There is also a significant correlation between small airways disease and quality of life (measured by the St. George’s Respiratory Questionnaire) as well as between small airways disease and dyspnea (measured by the modified Medical Research Council Scale) (both $P<0.01$).

Small airways disease and emphysema are associated with FEV$_1$ decline, particularly in mild-to-moderate COPD. Treatments targeting the small airways in COPD may reduce the rate of emphysema progression. In fact, because small airways disease appears to precede the onset of emphysema, the development of treatments that specifically target small airways disease has the potential to treat progression of both airway and parenchymal disease.

**ASSESSMENT**

Small airways disease can be difficult to assess because of the small size and inaccessibility of the airways. Many methods are complex or invasive, and overall, there is no unanimously accepted approach. Different methods of assessment are described below and summarized in the Supplemental Table (available online at http://www.mayoclinicproceedings.org), with Figure 3 providing an infographic overview of these techniques and their outputs.

With small airways disease, traditional lung function tests may only become abnormal once there is a significant burden of disease. Hence, although spirometry is the gold standard for diagnosing COPD, FEV$_1$ is not an adequate measure of small airways disease. Small airways disease is associated with bronchodilator responsiveness in terms of volume (forced vital capacity [FVC]) but not in terms of flow (FEV$_1$). Indeed, FVC has been used as an indirect measure of small airways disease in several clinical trials. Forced expiratory flow between 25% and 75% of the FVC is another common measure of small airways abnormality, though there is conflicting evidence regarding its reliability. Other measures of expiratory flow include evaluation of maximal expiratory flow when 75%, 50%, or 25% of FVC remains. The ratio of forced expiratory volume in 3 and 6 seconds (FEV$_3$/FEV$_6$) has also emerged as an earlier and more sensitive marker of small airways disease compared with other spirometric measures, with low FEV$_3$/FEV$_6$ found to be associated with impaired computed tomography (CT) scanning measures of small airways disease in patients with normal FEV$_1$/FVC.

Furthermore, the Genetic Epidemiology of
COPD (COPDGene) Study reported that patients with a reduced FEV$_3$/FEV$_6$ had a higher degree of gas trapping, worse symptoms (according to both the St. George’s Respiratory Questionnaire and the modified Medical Research Council Scale), and worse functional indices (6-minute walk distance) than patients with FEV$_3$/FEV$_6$ greater than the lower limit of normal.$^{30,31}$

Body plethysmography—which provides a sensitive measure of gas trapping and lung hyperinflation—can be used to assess lung volumes, providing measures such as total lung capacity (TLC), functional residual capacity, inspiratory capacity, and residual volume (RV).$^{12,15}$ As TLC is commonly elevated in COPD, the ratio of RV/TLC may provide a more robust marker of gas trapping and small airways disease than RV alone.$^{13}$ Airways resistance—which provides a measure of airway obstruction—may also be assessed by body plethysmography by measuring the pressure required to drive airflow during tidal ventilation.$^5$ Diffusing capacity for carbon monoxide (also known as transfer factor of the lung for carbon monoxide), which indirectly measures the degree of gas transfer from alveoli to pulmonary capillary blood, has also been found to correlate with small airways disease.$^{32}$

Data from ever-smokers in the COPDGene cohort indicated that functional small airways disease correlates significantly with

![Dynamic hyperinflation in COPD](image)

**FIGURE 2.** Dynamic hyperinflation in COPD. This figure shows the effects of dynamic hyperinflation on lung volumes. In COPD, if the small airways are narrowed or obstructed and there is expiratory airflow limitation, the inhaled volume of air is greater than the exhaled volume and air is retained in the lung. Accordingly, individuals with COPD often have some degree of hyperinflation in their lungs, even at rest. During resting breathing (COPD: green line; healthy individual: blue line), a breath is inhaled to tidal volume and an equal volume is exhaled so that the FRC remains stable but is still increased in patients with COPD. During exertion, agitation, or anxiety, the tidal volume and breathing frequency increase (red line) with a reduction in expiratory time. Because the inspiratory volume is greater than the expiratory volume, the end-expiratory volume increases with each breath, leading to a progressive increase in FRC and reduction in IC. This results in an increasing sensation of dyspnea and consequent limitation of physical activity in COPD, COPD, chronic obstructive pulmonary disease; FRC, functional residual capacity; IC, inspiratory capacity.
The forced oscillation technique and impulse oscillometry are techniques that can be used to determine the mechanical properties of the lung. The forced oscillation technique and impulse oscillometry work by applying oscillating pressure variations of varying frequencies to the lung during normal tidal breathing, with the resulting pressure and flow changes measured at the mouth. Higher-frequency signals reflect the contribution of larger airways, whereas low frequencies reflect the whole lung; as such, the contribution of the small airways can be found by comparing the two.

Inert gas washout techniques such as the single-breath nitrogen washout test and multiple-breath nitrogen washout test may also be used to assess small airways disease. These techniques work by measuring the efficiency of gas mixing in the lungs, which varies according to the structure of the large and small airways and can therefore give an indication of small airways disease. The sensitivity of the multiple-breath washout test has been found in smokers, with evidence of small airways disease detected from more than 10 pack-years onward, compared with more than 20 pack-years onward when assessed using spirometry. An analysis of the slope of phase III, which forms part of the characteristic trace that is recorded during the single-breath nitrogen washout test (Figure 3), can provide further information on the differences in ventilation in different parts of the lung. Measurement of novel exhaled biomarkers, including exhaled nitric oxide, can give an indication of inflammation (particularly eosinophilic inflammation) in the lung, including its location within central or peripheral airways.

Lung Imaging techniques for visualizing the small airways (Supplemental Table and Figure 4) include high-resolution CT, which is increasingly being supplemented by parametric image response mapping. Hyperpolarized helium magnetic resonance imaging is another useful technique for evaluating regional lung function, including assessment of the distribution of ventilation and morphometry of the distal airways and lung parenchyma. Other imaging techniques include nuclear medicine (scintigraphy, single photon emission CT, and positron emission tomography) and functional respiratory imaging, which uses airway imaging techniques such as CT combined with computational fluid dynamic simulations to determine patterns of airflow and inhaled drug deposition. Another recent method uses CT imaging techniques to identify and assess the relative contributions of emphysematous and nonemphysematous gas trapping, thus helping to assess different COPD phenotypes.

Other techniques to assess small airways are more invasive and typically only used for research purposes, for example, sputum induction after inhalation of hypertonic saline, bronchoalveolar lavage, and endobronchial and transbronchial biopsies.

For the assessment of dynamic hyperinflation and ventilatory limitation, exercise testing is a commonly used clinical tool that is easy to implement. Measurement of tidal exercise flow volume loops can provide sensitive data on the extent of expiratory flow limitation, inspiratory flow reserve, and alterations in dynamic hyperinflation and tidal volume/inspiratory capacity and may enable earlier detection of abnormalities than other approaches. Constant work rate endurance protocols are also an effective patient-centered method to assess the response to therapeutic interventions in patients with COPD.

PREVENTION

Although it is not the primary focus of this article, it is important to note that prevention is the best means to tackle the global burden of small airways disease and COPD. This can be achieved by implementing effective smoking cessation programs and reducing environmental exposure to biomass fuels and air pollution; however, this is difficult to achieve in practice.
FIGURE 3. Measurement of small airways disease: physiological techniques. COPD, chronic obstructive pulmonary disease; CV, closing volume; ERV, expiratory reserve volume; FENO, fractional exhaled nitric oxide; FEV1/3/6, forced expiratory volume in 1/3/6 second(s); FRCpleth, functional residual capacity measured using plethysmography; FVC, forced vital capacity; IC, inspiratory capacity; IRV, inspiratory reserve volume; MEF25/50/75, maximal expiratory flow when 25%/50%/75% of forced vital capacity remains; MMEF, maximal mid-expiratory flow; NO, nitric oxide; PEF, peak expiratory flow; RV, residual volume; SVC, slow vital capacity; TLC, total lung capacity; VT, tidal volume.
TREATMENT

What Treatments Are Available to Target the Small Airways?

Directing drugs to the small airways via the inhaled route has a number of advantages compared with oral or intravenous routes. For example, smaller drug doses can be used, the onset of action is more rapid, and the incidence of adverse effects—particularly those of corticosteroids—is reduced.46,47

The choice of both the drug molecule and the inhaler device is critical, particularly when considering how best to enhance drug deposition at the site of disease. As well as the total dose of drug delivered to the lungs, the regional deposition pattern within the lungs is an important factor.47,48 As most inhaled therapies do not sufficiently reach the small airways, it is necessary to improve the precision of drug deposition to increase the efficiency and effectiveness of inhaled drug delivery.49,50 Different therapeutic options with the potential to target the small airways are described below and are summarized in the Table.14,57-81
FIGURE 4. Measurement of small airways disease: imaging techniques. COPD, chronic obstructive pulmonary disease. Reprinted from Contoli M, et al. Allergy. 2010;65(2):141-151. https://doi.org/10.1111/j.1398-9995.2009.02242.x. © 2009 John Wiley & Sons A/S.  
Reprinted with permission from Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. Kirby M, et al. COPD F. 2014;1(2):200-211. http://doi.org/10.15326/jcopdf.1.2.2014.0136. © 2014 The COPD Foundation.  
Adapted with permission of the American Thoracic Society. Copyright © 2020 American Thoracic Society. Readers are encouraged to read the entire article for the correct context at https://doi.org/10.1164/rccm.200410-1414OC. The authors, editors, and the American Thoracic Society are not responsible for errors or omissions in adaptations.  
Images from Burrowes KS, et al. J Transl Med. 2014;12:S5. Published by BioMed Central Ltd. This work is licensed under a Creative Commons Attribution (CC BY) 4.0 License.  
Images from Occhipinti M, et al. Aging Dis. 2017;8(4):471-485. Published by Aging and Disease. This work is licensed under a Creative Commons Attribution (CC BY) License.
Drug Formulations Optimized to Reach the Small Airways

Recent advances in inhaled drug delivery have improved delivery of aerosolized medicine to the small airways. Many factors can influence the deposition of medical aerosols in the lung, including characteristics such as size, density, and charge of drug particles (with smaller particles being preferable), lipophilicity/hygroscopicity of formulation, and speed and duration of aerosol spray (with slower inhalation flow being preferable). Patient-specific factors are also important, including the patient’s breathing pattern and inhalation technique (inspiratory flow, inhaled volume, and breath-hold pause), severity of disease, and device acceptance and adherence. In particular, particle size plays a key role in determining the fate of the aerosolized medicine within the respiratory tract, with larger particles being deposited in the oropharynx, trachea, and upper bronchial tree and smaller particles able to reach the distal airways. To ease differentiation, particle size can be classified as extrafine, fine, or coarse according to whether the mass median aerodynamic diameter is less than 2.1, 2.1 to 5, or greater than 5 μm, respectively.

### TABLE. Therapeutic Options to Target Small Airways Disease

| Novel formulations | Mechanism of action |
|--------------------|---------------------|
| Extrafine particle ICS/LABA formulations | • Beclomethasone dipropionate + formoterol fumarate  
• Beclomethasone dipropionate + formoterol fumarate + glycopyrromonium bromide  |
| Co-suspension LAMA/LABA formulation (Bevespi Aerosphere) | • Glycopyrrolate/formoterol fumarate, formulated using a novel co-suspension delivery technology for administration via MDI |
| Extrafine particle ICS | • Extrafine particle size enhances delivery to small (as well as large) airways |

| Novel inhalers/inhalation systems | Mechanism of action |
|----------------------------------|---------------------|
| Respimat® Soft Mist™ inhaler | • Respimat droplets deposit more uniformly in the different lung regions compared with particles from dry powder inhalers  
• Respimat exhibited a higher proportion of particles reaching all parts of the lung than did DPIs |
| Adaptive Aerosol Delivery (AAD®) system | • Adapts to changes in patient’s breathing pattern and pulses aerosol during the inspiratory part of the breathing cycle |
| AKITA® inhalation system | • Uses individualized controlled inhalation to optimize the inhalation maneuver of the patient |

| Other agents in development | Mechanism of action |
|-----------------------------|---------------------|
| Inhaled antibiotics | • Combined antimicrobial and anti-inflammatory effects |
| Alpha-1 antiprotease | • Inhibition of proteases involved in the progression of disease |
| Anti-inflammatory compounds, eg, monoclonal antibodies | • Target molecules involved in the inflammatory cascade such as cytokines |
| Mucolytic agents | • Reduce viscosity of the sputum; antioxidant effects |

DPI, dry powder inhaler; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; MDI, metered-dose inhaler.
Recently developed inhaled formulations that optimize delivery to the small airways include extrafine inhaled corticosteroid (ICS), ICS/long-acting β2-agonist (LABA) formulations (eg, ciclesonide and beclomethasone dipropionate/formoterol fumarate), and ICS/LABA/long-acting muscarinic antagonist (LAMA) formulations (eg, beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide). These agents have been evaluated for use in small airways disease both in COPD and in asthma. A novel fixed-dose LAMA/LABA combination of glycopyrrolate/formoterol fumarate has also been formulated using co-suspension delivery technology for administration via a pressurized metered-dose inhaler (pMDI; Bevespi Aerosphere; AstraZeneca, Cambridge, UK). Clinical findings from a scintigraphy study reported that doses of glycopyrrolate/formoterol fumarate pMDI were deposited in both central and peripheral lung regions, revealing that this approach can successfully target the small airways and provide a further treatment option for patients who prefer to use a pMDI, such as those who may be unable to achieve the minimum inspiratory flow rate necessary to use a dry powder inhaler (DPI).

For patients who require ICS in addition to bronchodilator therapy, it may be beneficial to target the small airways with extrafine particle formulations. The FOsteR 48-Week trial to reduce exacerbations in COPD (FORWARD) study reported that compared with formoterol alone, extrafine beclomethasone/formoterol significantly reduced the exacerbation rate and improved lung function in patients with severe COPD and a history of exacerbations. In another study by Tzani et al, extrafine beclomethasone/formoterol significantly reduced air trapping and dyspnea in patients with COPD and lung hyperinflation when compared with fluticasone/salmeterol. Furthermore, findings from the randomized controlled trial TRILOGY suggest that triple therapy with extrafine beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed-dose combination can reduce moderate and severe exacerbations more effectively than ICS/LABA combination therapy. There is also evidence that extrafine beclomethasone at lower doses is equivalent to fluticasone at higher doses in terms of reducing exacerbations, with improved treatment stability over a 2-year period, suggesting greater lung deposition of extrafine beclomethasone to the small airways. This is supported by a recent study, which used a model approach based on functional respiratory imaging computer simulations. This revealed that extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide had higher peripheral deposition of all three components (ICS, LABA, and LAMA) compared with a non-extrafine formulation of fluticasone furoate/vilanterol/umeclidinium on the basis of profiles from patients with moderate-to-very severe COPD. It must be noted, however, that research supporting the benefits of enhanced drug delivery to the small airways on patient-centered outcomes is limited.

Using lower doses of ICS is also likely to be associated with a reduced risk of adverse events. Findings from a real-life COPD study suggest that patients taking extrafine particle ICS have a lower risk of pneumonia than those taking fine-particle ICS. In addition, data from patients with asthma suggest that extrafine particle ICS is associated with an improved chance of asthma control and lower exacerbation rates at significantly lower ICS doses as compared with fine-particle ICS.

Inhalers Optimized to Reach the Small Airways

Conventional pMDIs and most DPIs emit drug particles that are too large to effectively target the small airways. However, some newer DPIs such as the NEXThaler (Chiesi, Manchester, UK) have been developed to deliver extrafine particles that can reach them. Inhaler technique also has an important role in ensuring efficient delivery of drug.

Inhaler delivery efficiency is another important factor affecting the level of deposition in the small airways. For example, the Respimat® Soft Mist™ inhaler (Boehringer Ingelheim, Ingelheim, Germany) produces aerosol droplets with a diameter of 1 to
5.8 μm to ensure efficient lung deposition while avoiding loss of small droplets during exhalation.70 The fine particle fraction is approximately 75% for Respimat with most formulations (range, 65%-80%), representing nearly double the value reported for aerosols generated by conventional pMDIs and DPIs.70,93 Coupled with the low velocity and long generation time of the aerosol, this means that more of the emitted dose is deposited in the lungs and less in the oropharynx compared with aerosols from other inhalers.70-73,94 This is supported by a combined in vitro/in silico model of COPD, in which Respimat exhibited the lowest throat deposition and the highest deposition in the whole lung and in different lung generations, compared with the tested DPIs.93 Further support has been provided by an in vivo scintigraphy study, which revealed similar Respimat deposition data to the in vitro analyses.95

Novel aerosol delivery systems such as the Adaptive Aerosol Delivery (AAD®, Philips Respironics, Murrysville, PA) system may also be of use in small airways disease. These are designed to continuously adapt to changes in the patient’s breathing pattern so that they pulse aerosol only during the inspiratory part of the breathing cycle, thus eliminating waste and ensuring precise aerosol delivery.74 Another aerosol delivery system that actively controls the entire inhalation maneuver of the patient is the AKITA® inhalation system (Activaero, Gemünden, Germany).75 This uses information delivered by a computer-controlled compressor programmed from the patient’s own individual lung function data.75

Drugs Aimed at Improving Small Airway Function
In addition, there is significant ongoing interest in the development and application of both existing and novel drugs to target the small airways, including inhaled antibiotics, anti-inflammatory compounds, monoclonal antibodies, antiprotease therapy, and mucolytic agents.76-80,96

Macrolide antibiotics, which are commonly used in cystic fibrosis and other forms of bronchiectasis, may be of use in patients with small airways disease caused by underlying infection and inflammation.96 Efforts are underway to develop inhaled formulations of these drugs, which may have a lower risk of systemic toxicity, for example, QT prolongation and ototoxicity.76

Mucolytic agents are associated with modest reductions in exacerbations and improvements in quality of life in some studies81,97 and could have a role in long-term management of COPD. In a study comparing the mucolytic agent N-acetyl cysteine with placebo, N-acetyl cysteine was found to provide significantly greater improvements in measures of small airways function, forced expiratory flow at 25% to 50%, and forced oscillation technique.81

FUTURE DIRECTIONS
Despite growing insight into small airways disease, a number of questions have so far remained unanswered in our understanding of the area. Early detection remains the key barrier, although we have outlined several new approaches that have the potential to achieve this goal. Critically, if detected early, treatment with therapy options designed to target small airways should help slow disease progression, reduce symptoms, and help patients maintain their activities. It may therefore be beneficial to further investigate whether the ability to target treatments to the lung periphery and increase lung deposition could slow disease progression in patients with COPD and thereby become a viable treatment option for patients who have small airway involvement and early signs of COPD.

Recent increases in understanding concerning the inflammatory pathways underlying COPD are also giving rise to the development of targeted therapies, such as biologics and small molecules.79 As small airways are the major site of obstruction, caused by airway remodeling and accumulation of inflammatory exudates,79 treatments targeted to the small airways may be particularly beneficial. However, despite significant
interest in cytokines and chemokines as a therapeutic target in COPD, there is a need for novel targets that are more specific and have a reduced adverse effect profile. A80

Another possible target in COPD is to address protease-antiprotease imbalance, which may be involved in the pathology of small airways disease. Recent evidence suggests that enhanced protease activity is associated with small airway remodeling and that serine protease inhibitors may be a potential therapeutic target for small airways disease.

Studies are needed that compare outcomes obtained by traditional management of COPD (ie, according to GOLD recommendations) with those based on small airway-directed management. Moreover, evidence is required to find the possible role of new drugs in the development for treating small airways disease, as well as novel drug formulations, inhalers, and inhalation devices. It will be of particular interest to discern whether the progression of COPD can be slowed in some patients after they stop smoking by targeting the inflammation in the small airways.

It is important to recognize that the characterization and targeted treatment of small airways is just one component of a broader strategy to evaluate the phenotypic variations of patients with COPD to provide them with the most effective and appropriate targeted therapy. This comprehensive diagnostic and management strategy includes many different modalities, including immunizations, oxygen therapy, lung volume reduction surgery, bronchoscopic lung volume reduction, pulmonary rehabilitation, mindfulness, and breathing techniques, in addition to pharmacological therapy. These are discussed in more detail elsewhere. A7

Finally, we have concentrated here on treating disease, but it is also important to consider prevention of COPD by reducing environmental exposure to biomass fuels in third world countries and reducing particulate and gaseous air pollution in major metropolitan areas.

CONCLUSION
Both preventable and treatable, small airways disease has important clinical consequences if left unchecked. Small airways disease is associated with poor spirometry results, increased lung hyperinflation, and poor health status, making the small airways an important treatment target in COPD. Further advances in our ability to assess the extent of small airways involvement, as well as the use of novel drugs, formulations, and inhalers that target the small airways, will help improve our management of small airways disease in patients with COPD.

ACKNOWLEDGMENTS
Editorial support was provided by Cindy Macpherson, PhD, of MediTech Media, UK, and was funded by Boehringer Ingelheim.

SUPPLEMENTAL ONLINE MATERIAL
Supplemental material can be found online at: http://www.mayoclinicproceedings.org. Supplemental material attached to journal articles has not been edited, and the authors take responsibility for the accuracy of all data.

Abbreviations and Acronyms: COPD = chronic obstructive pulmonary disease; CT = computed tomography; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FEV3 = forced expiratory volume in 3 seconds; FEV6 = forced expiratory volume in 6 seconds; FVC = forced vital capacity; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; pMDI = pressurized metered-dose inhaler; RV = residual volume; TLC = total lung capacity

Potential Competing Interests: Dr Usmani has received industry-academic funding from AstraZeneca, Boehringer Ingelheim, Chiesi, Edmond Pharma, GlaxoSmithKline, and Mundipharma International and has received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Edmond Pharma, GlaxoSmithKline, Napp, Novartis, Mundipharma International, Pearl Therapeutics, Roche, Sandoz, Takeda, Trudell Medical International, UCB, Vectura, and Zentiva. Dr Dhand has received fees for advisory boards from Bayer, Boehringer Ingelheim, AstraZeneca, and Mylan. Dr Lavorini has received grants for research or fees for speaking and advisory boards from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini International, Novartis, Orion Pharma, and Trudell Medical International. Dr Price has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and Teva Pharmaceuticals; has consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; has received grants and
unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, the British Lung Foundation, Chiesi, Circassia, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, and Zentiva (Sanofi Generics); has received payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, and Teva Pharmaceuticals; has received payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; has received payment for the development of educational materials from Mundipharma and Novartis; has received payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Circassia, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; has received funding for patient enrollment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva (Sanofi Generics); received stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and the UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation program and Health Technology Assessment.

Correspondence: Address to Omar S. Usmani, FRCP, National Heart and Lung Institute (NHLI), Imperial College London, Dovehouse St, London SW3 6LY, UK (o.usmani@imperial.ac.uk).

ORCID
Omar S. Usmani  https://orcid.org/0000-0002-4367-254X

REFERENCES

1. Burgel PR. The role of small airways in obstructive airway disease [published corrections appear in Eur Respir Rev. 2011;20(119):23-32].

2. Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med. 2012;44(2):146-156.

3. Hogg JC, Macklem PT, Thrushbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278(25):1355-1360.

4. Higham A, Quinn AM, Cançado JED, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res. 2019;20(4):49.

5. Stockley JA, Cooper BG, Stockley RA, Sapey E. Small airways disease: time for a revisit? Int J Chron Obstruct Pulmon Dis. 2017;12:2234-2253.

6. Crisafulli E, Poi R, Aulito M, et al. Prevalence of small airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respir Med. 2017;93(3):324-41.

7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 report). 2019. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed June 4, 2021.

8. Brado F, Scichilone N, Lavorini F, et al. Interasma Executive Board; WAO Board of Directors; ARIA; GA2LEN. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN). Asthma Res Pract. 2016;6(2):12.

9. Pui R, Aelio M, Zanini A, et al. Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:191-1197.

10. Lynch DA, Austin JH, Hogg JC, et al. CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischer Society. Radiology. 2015;277(1):92-205.

11. Paoletti M, Camicciottoli G, Meoni E, et al. Explorative data analysis techniques and unsupervised clustering methods to support clinical assessment of chronic obstructive pulmonary disease (COPD) phenotypes. J Biomed Inform. 2009;42(6):1013-1021.

12. Bonini M, Usmani OS. The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2015;9(6):281-293.

13. Hogg JC, Paré PD, Hackett TL. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease [published correction appears in Physiol Rev. 2018;98(3):1099]. Physiol Rev. 2017;97(2):529-552.

14. Singh D. Small airway disease in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2017;80(4):317-324.

15. McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. Eur Clin Respir J. 2014;1.

16. Hogg JC, McDonough JE, Sanchez PG, et al. Micro-computed tomography measurements of peripheral lung pathology in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(6):546-549.

17. Bhatt SP, Soler X, Wang X, et al. COPDGene Investigators. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178-184.

18. MacNee W, Murchison JT. Small airway disease or emphysema: which is more important in lung function and FEV1 decline? An old story with a new twist. Am J Respir Crit Care Med. 2016;194(2):129-130.

19. Soffler ML, Hayes MM, Schwartzstein RM. Respiratory sensations in dynamic hyperinflation: physiological and clinical applications. Respir Care. 2017;62(9):1212-1223.

20. Thomas M, Decramer M, O’Donnell DE. No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J. 2013;22(1):101-111.

21. Eichinger M, Walterspacher S, Scholz T, et al. Lung hyperinflation: foe or friend? Eur Respir J. 2008;32(4):1113-1116.

22. O’Donnell DE, Webb KA, Neder JA. Lung hyperinflation in COPD: applying physiology to clinical practice. COPD Res Pract. 2015;1. article no. 4.

23. Seth S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465-471.

24. Sand JM, Martinez G, Midjord AK, Karsdal MA, Leeming DJ, Lange P. Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in clinically stable chronic obstructive pulmonary disease. Clin Biochem. 2016;49(15):1144-1151.

25. Schumann DM, Leeming D, Papaikontantinou E, et al. Collagen degradation and formation are elevated in exacerbat ed COPD compared with stable disease. Chest. 2018;154(4):798-807.

26. Malia-Milanes B, Dufour A, Philip C, et al. TAILS proteomics reveals dynamic changes in airway proteolysis controlling
protease activity and innate immunity during COPD exacerbations. Am J Physiol Lung Cell Mol Physiol. 2018;315(6):L1003-L1014.

27. Papakonstantinou E, Karakulakis G, Batzios S, et al. Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespective of airway obstruction, emphysema and infection. Respir Res. 2015;16(1):78.

28. Haruna A, Oga T, Muro S, et al. Relationship between peripheral airway function and patient-reported outcomes in COPD: a cross-sectional study. BMC Pulm Med. 2010;10:10.

29. Usmani OS. Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol. Res. 2014;6(5):376-388.

30. Dilektasi AG, Porszasz J, Casaburi R, et al. COPD Gene Investigators. A novel spirometric measure identifies mild COPD unidentifiable by standard criteria. Chest. 2016;150(5):1080-1090.

31. Dean J, Kolsum U, Hitchen P, Gupta V, Singh D. Clinical characteristics of COPD patients with tidal expiratory flow limitation. Int J Chron Obstruct Pulm Dis. 2017;12:1503-1506.

32. Paredi P, Goldman M, Alam A, et al. Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. Thorax. 2010;65(3):263-267.

33. Verbanck S, Galbán CQ, Ross BD, et al. Parametric response mapping on chest computed tomography associates with clinical and functional parameters in chronic obstructive pulmonary disease. Respir Med. 2017;123:48-55.

34. Hoffman BA, Pompe EE, Galbán CQ, et al. CT-based local distribution metric improves characterization of COPD. Sci Rep. 2017;7(1):12999.

35. De Backer JW, Vos WG, Vinchurkar SC, et al. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J Aerosol Med Pulm Drug Deliv. 2015;28(2):88-99.

36. De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257(3):854-862.

37. Iwanga T, Kozuka T, Nakashima J, et al. Aerosol deposition of inhaled corticosteroids/long-acting β2-agonists in the peripheral airways of patients with asthma using functional respiratory imaging: a novel imaging technology. Pulm Ther. 2017;3:219-231.

38. Occhipinti M, Paoletti M, Bigazzi F, et al. Emphysematous and nonemphysematous gas trapping in chronic obstructive pulmonary disease: quantitative CT findings and pulmonary function. Radiology. 2018;287(2):683-692.

39. Johnson BD, Weissman IM, Zeballos RJ, Beck KC. Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. Chest. 1999;116(2):488-503.

40. Guenette JA, Chin RC, Cory PM, Weba KA, O’Donnell DE. Inspiratory capacity during exercise: measurement, analysis, and interpretation. Pulm Med. 2013;2013:956081.

41. Borel B, Provencher S, Saey D, Maitais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med. 2013;2013:410748.

42. Rube KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931-1940.
beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J Chron Obstruct Pulmon Dis. 2017;12:297-298.

66. Ferguson GT, Rodriguez-Roisin R, Reisner C, Maes A, Siddiqui S, Martin UJ. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3945-953.

67. D’Urzo AD, Cazzola M, Hanania NA, Buhl R. Maleki-Yazdi MR. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrronium/formoterol combination formulated by co-suspension delivery technology. Int J Chron Obstruct Pulmon Dis. 2018;13:2805-2819.

68. Postma DS, Roche N, Colice G, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis. 2014;2:1163-1186.

69. Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565-1577.

70. Dalby RN, Eicher J, Zierenberg B. Development of Respimat Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckland). 2011;4:145-155.

71. Anderson P, Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251-259.

72. Piccinò G, Reader S, Pawa D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264-272.

73. Hochrainer D, Hölz H, Kreher C, Scafidi F, Petrini O. Mucoactive agents in the therapy of upper respiratory airways infections: fair to describe them just as mucocidal? Curr Opin Pulm Med. 2008;14(suppl 4):71-77.

74. Seemüller R, Hofmann T, Scheuch G. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. Adv Exp Med Biol. 2015;839:13-24.

75. Strange C. Anti-proteases and alpha-1 antitrypsin augmentation therapy. Respir Care. 2018;63(6):690-698.

76. Usmani OS, Scichilone N, Mignot B, et al. Airway deposition of extrafine inhaled triple therapy in patients with COPD: a model approach based on functional respiratory imaging computer simulations. Int J Chron Obstruct Pulmon Dis. 2020;15:2433-2440.

77. Sonnappa S, Martin R, Israel E, et al; Respiratory Effectiveness Group. Small Airways Study Group. Risk of pneumonia in obstructive lung disease: a real-life study comparing extrafine and fine-particle inhaled corticosteroids. PlaS One. 2017;12(6):e0178112.

78. Sonnappa S, McQueen B, Postma DS, et al. Extrafine versus inhaled corticosteroids in relation to asthma control: a systematic review and meta-analysis of observational real-life studies. J Allergy Clin Immunol Pract. 2018;6(3):907.e907.

79. Usmani OS, Chrysanthou V, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma [published correction appears in Expert Opin Drug Deliv. 2014;11(9):1827]. Expert Opin Drug Deliv. 2014;11(9):1497-1506.

80. Kaplan A, Price D. Matching inhaler devices with patients: the role of the primary care physician. Can Respir J. 2018;25(3):9473051.

81. Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16:113-135.

82. Iwanga T, Tohda Y, Nakamura S, Suga Y. The Role of the Primary Care Physician. The Respiratory Effectiveness Group. Small Airways Study Group. Risk of pneumonia in obstructive lung disease: a real-life study comparing extrafine and fine-particle inhaled corticosteroids. PlaS One. 2017;12(6):e0178112.

83. Taylor G, Warren S, Dwivedi S, et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;114:450-457.